By opening a new business line in clinical bioanalysis, this acquisition marks a key milestone in the Group’s objective to offer a continuum from target to patient. This integration also promises to accelerate the development of safer and more targeted treatments, ensuring better quality medical care.
Firalis Molecular Precision: biomarker expertise at every stage of development
- Discovery Phase: Firalis Molecular Precision (FMP) leverages a comprehensive multi-omic approach to explore in-depth the discovery and validation of target biomarkers, with expertise in elucidating complex mechanisms of action.
- Preclinical Research: FMP offers biomarker studies, drug safety and efficacy evaluation.
- Clinical Development: Firalis Molecular Precision characterizes patients’ genetic profiles, analyzes adverse effects, drug activity and efficacy, discovers prognostic and diagnostic biomarkers, offers companion tests, and clinically validates response signatures.
Cutting-Edge Technologies
Firalis Molecular Precision relies on advanced technological platforms to ensure precision and sensitivity in its analyses. In genomics, the company uses next-generation sequencing for genetic and epigenetic profiling and custom gene expression, digital PCR to detect rare mutations and quantify low-abundance targets with absolute precision, as well as customized real-time PCR. In proteomics, Firalis Molecular Precision utilizes Olink technology for large-scale protein identification, enabling simultaneous analysis of several thousand proteins in a single sample, as well as customized solutions for large-scale clinical monitoring, complemented by a comprehensive and ultra-sensitive proteomic platform for precise protein quantification. This combination of approaches provides a complete picture from genes to functional proteins, also integrating the analysis and integration of all omic data.
Firalis Molecular Precision within Janvier Group
FMP’s expertise in biomarkers will accelerate discovery, strengthen the predictive value of preclinical studies, and improve clinical development through stratification and monitoring tools. With the acquisition of this company, Janvier Group Biosciences is now able to support its clients on all issues related to the development of drug candidates, from the initial efficacy and toxicity phases to clinical phases through biomarker analysis. This new expertise strengthens the Group’s ability to accelerate and secure the development of innovative molecules.
“We are proud to welcome the employees of Firalis Molecular Precision – who have been doing excellent work for several years – into Janvier Group Biosciences. We are also very pleased to be able to offer our partners a new high-value-added activity, in full synergy with our other companies.” Thomas Janvier, CEO of Janvier Group Biosciences